Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate ...

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...

The European Union (EU) is actively courting biotech for economic growth and has launched several initiatives to attract ...

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

In the rapidly evolving landscape of pharmaceutical development, AI promises to revolutionize the entire drug discovery and development process, impacting target discovery, clinical trial design, site ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...

Changing healthcare provider (HCP) and patient expectations have disrupted conventional customer engagement methods across the entire healthcare ecosystem. The traditional reach and frequency model ...

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...